MTL-007 – The Protides Platform (Acelarin) – ProTides programme, a fully funded product named Acelarin which is out licenced to Nucana (see: http://nucana.com)
By 2019 Acelarin will be ready to submit to the European Agency to obtain marketing approval for Pancreatic Cancer, in late stage Phase 3 Clinical trials for Ovarian Cancer and late Phase 2 clinical trials for Biliary Cancer.
Morvus’ Pro-Tide technology has been shown to improve the therapeutic index of established chemotherapeutic molecules hence it is applicable to a broad range of tumours.
Gemcitabine is also licensed for use alone or in combination with other chemotherapeutics in patients with Bladder, Lung and Biliary Cancer. This confers low development risk, fast development cycles and clearly defined commercial potential. The results from the Phase 1 and 2 clinical trials conducted at Hammersmith Hospital provided statistically significant evidence of MTL-007 (Acelarin) safety and efficacy profiles (see: http://www.bbc.co.uk/news/uk-wales-32917141).
MTL-005 – MOREX – is a 50/50 Joint Venture Partnership with Morvus and Stephens Inc the latter with the sole responsibility for financing MoreEx the product being a Radiosensitiser that has been demonstrated to significantly enhance the effect of radiation – (coppermeso-5.15-bis[3-[1,2-dicarba-closo-dodecaboanyl] methoxy]phenyl]-meso-10,20-dinltropropphyrin) in the treatment of Cancer cells for Head and Neck Cancer.
The compound is non-cytotoxic but is activated by radiation doubling the effectiveness of the radiation therapy.
This product is undergoing Clinical trials to complete by Mid- 2017 to enter pivotal Phase 2b study to be completed by 2019 and will be moving towards market approval. If this product is successful, and all reports suggest it is very effective, it will lead to a ‘liquidity event’ by end of 2018 early 2019.
Morvus placed MTL-005 into a Joint Venture (JV) company, MorEx Development Partners (MDP) and in June 2013 the European Commission granted MDP orphan designation (EU/3/13/1138) for patients with Biliary Cancers undergoing radiotherapy.
(see: MorEx Article April 2018)